Overall market sentiment has been neutral on Zymeworks Inc (ZYME) stock lately. ZYME receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.
Zymeworks Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ZYME!
In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With ZYME Stock Today?
Zymeworks Inc (ZYME) stock has fallen -4.83% while the S&P 500 has risen 1.39% as of 1:36 PM on Tuesday, Oct 5. ZYME is down -$1.39 from the previous closing price of $28.77 on volume of 566,001 shares. Over the past year the S&P 500 has risen 27.92% while ZYME is down -38.69%. ZYME lost -$4.35 per share in the over the last 12 months.
To screen for more stocks like Zymeworks Inc click here.
More About Zymeworks Inc
Zymeworks Inc is a clinical-stage company. It is dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer. The company's product candidate, ZW25, is a bispecific (dual-targeting) antibody being evaluated in an adaptive Phase 1 clinical trial, targeting two distinct domains of the human epidermal growth factor receptor 2, or HER2. Its design enables ZW25 to address patient populations with all levels of HER2 expression, including those with low to intermediate HER2-expressing tumors, who are otherwise limited to chemotherapy or hormone therapy.
Click Here to get the full Stock Report for Zymeworks Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
